Anuh Pharma
NSE: ANUHPHR · Pharmaceuticals
Snapshot
Unlock Anuh Pharma's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Anuh Pharma Limited is an Indian pharmaceutical company specialising in the manufacture and sale of bulk drugs and active pharmaceutical ingredients (APIs). Its diverse product portfolio spans therapeutic categories including macrolides, anti-TB, anti-bacterial, and corticosteroids, serving both domestic and international markets.
Business Model
The company generates revenue through the large-scale production and distribution of APIs and chemical intermediates. It operates as a B2B supplier, catering to pharmaceutical formulators globally.
- Incorporation Year:1960
Growth Outlook
Growth is driven by the expansion of its specialised API portfolio and the continued development of new therapeutic products. The company leverages its established manufacturing capabilities to capture demand in both domestic and export markets.
Key Risks
- Regulatory Compliance. The company is subject to stringent quality standards and inspections by global health authorities, where non-compliance could lead to export bans.
- Raw Material Price Volatility. Fluctuations in the cost of key starting materials and chemical intermediates can significantly impact operating margins.
- Foreign Exchange Risk. As an exporter, the company is exposed to currency fluctuations that may affect the competitiveness and profitability of its international sales.
- Competitive Intensity. The bulk drug industry is highly fragmented, leading to intense price competition from both domestic and international manufacturers.
Start your research today
Unlock AI insights, financials, peers and live data on Anuh Pharma and 5,000+ companies — free.
Key Metrics
REVENUE
₹778 Cr
TTM · standalone
NET PROFIT
₹48 Cr
TTM · standalone
EPS
₹4.77
TTM · standalone
RETURN ON EQUITY
13.9%
TTM · standalone
RETURN ON CAPITAL EMPLOYED
19.0%
TTM · standalone
P/E
17.7×
Q2 FY27 · standalone
EV/EBITDA
11.6x
Q2 FY27 · standalone
EBITDA MARGIN
9.8%
TTM · standalone
NET PROFIT MARGIN
6.1%
Q2 FY27 · standalone
DEBT TO EQUITY
0.1x
Q2 FY27 · standalone
Peers · Pharmaceuticals
| Company | Mkt Cap | P/E (TTM) | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Anuh PharmaANUHPHR | ₹875 Cr | 17.7× | 11.58 | 6.6% | 9.8% | 13.9% | 19.0% | -5.8% |
Sigachi Industries LimitedSIGACHI | ₹1,007 Cr | 39.2× | 18.76 | -3.1% | 12.4% | 4.7% | 7.2% | -29.6% |
Lincoln Pharmaceuticals LimitedLINCOLN | ₹1,000 Cr | 10.6× | 6.81 | 14.2% | 20.0% | 12.7% | 16.4% | -3.3% |
Themis MedicareTHEMISMED | ₹873 Cr | 23.2× | -29.56 | -12.8% | -9.9% | 10.0% | 11.3% | -18.8% |
Shree Ganesh Remedies LimitedSGRL | ₹792 Cr | 63.5× | 27.22 | -13.6% | 32.0% | 7.6% | 10.2% | +20.7% |
Zim LaboratoriesZIMLAB | ₹731 Cr | 164.4× | 21.21 | 7.6% | 9.9% | 1.3% | 5.7% | +84.0% |
As of Q2 FY27
Financials
Anuh Pharma
NSE: ANUHPHR · Pharmaceuticals
Snapshot
Unlock Anuh Pharma's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Anuh Pharma Limited is an Indian pharmaceutical company specialising in the manufacture and sale of bulk drugs and active pharmaceutical ingredients (APIs). Its diverse product portfolio spans therapeutic categories including macrolides, anti-TB, anti-bacterial, and corticosteroids, serving both domestic and international markets.
Business Model
The company generates revenue through the large-scale production and distribution of APIs and chemical intermediates. It operates as a B2B supplier, catering to pharmaceutical formulators globally.
- Incorporation Year:1960
Growth Outlook
Growth is driven by the expansion of its specialised API portfolio and the continued development of new therapeutic products. The company leverages its established manufacturing capabilities to capture demand in both domestic and export markets.
Key Risks
- Regulatory Compliance. The company is subject to stringent quality standards and inspections by global health authorities, where non-compliance could lead to export bans.
- Raw Material Price Volatility. Fluctuations in the cost of key starting materials and chemical intermediates can significantly impact operating margins.
- Foreign Exchange Risk. As an exporter, the company is exposed to currency fluctuations that may affect the competitiveness and profitability of its international sales.
- Competitive Intensity. The bulk drug industry is highly fragmented, leading to intense price competition from both domestic and international manufacturers.
Start your research today
Unlock AI insights, financials, peers and live data on Anuh Pharma and 5,000+ companies — free.
Key Metrics
REVENUE
₹778 Cr
TTM · standalone
NET PROFIT
₹48 Cr
TTM · standalone
EPS
₹4.77
TTM · standalone
RETURN ON EQUITY
13.9%
TTM · standalone
RETURN ON CAPITAL EMPLOYED
19.0%
TTM · standalone
P/E
17.7x
Q2 FY27 · standalone
EV/EBITDA
11.6x
Q2 FY27 · standalone
EBITDA MARGIN
9.8%
TTM · standalone
NET PROFIT MARGIN
6.1%
Q2 FY27 · standalone
DEBT TO EQUITY
0.1x
Q2 FY27 · standalone
Peers · Pharmaceuticals
As of Q2 FY27